Skip to main content
  • NYTimes.com: 2 New Ebola Vaccines Pass Important Early Test, Researchers Say

    Vaccines Made by Profectus BioSciences

    Read More
  • BREETHE AIMS TO BRING FIRST WEARABLE ‘OUT-OF-HOSPITAL’ ARTIFICIAL LUNG SYSTEM TO MARKET

    UMB Invests $100K in Company and Licenses Technology to New Startup

    Read More
  • UMB Pres. Perman Stresses Role of Academia in Driving Local Biotech Cluster’s Success

    How Academia Can Advance Maryland/Virginia/DC Region’s Biotech Cluster

    Read More
  • HOT TECH: DMXAA as an Anti-Viral Agent

    DMXAA, a drug developed as an anti-cancer agent, can stop even drug-resistant influenza strains from replicating in vitro.

    Learn More
  • Discovery by UM School of Medicine Researchers Uncovers Possible New Mechanism Behind Retinal Ailment That Affects Millions

    New study finds that common degenerative eye disease may be triggered by tiny mineral deposits in the eye

    Learn More
  • Hot Technologies Available for Licensing

    UM Ventures is organized to move research outcomes into products and services, tools and diagnostics that will benefit society.

    Learn More

Receive Tech Alerts

Sign up to receive current new technology announcements and other UM Ventures news.

Select Your Interest(s)

Proudly showcasing UM Ventures Companies

In the last two years, UM Ventures has increased technology licenses by 46 percent (28 in FY11 vs. 41 in FY13) and new startup companies created by UM faculty increased by 120 percent (5 in FY11 to 11 in Fy13).

University of Maryland, College Park
University of Maryland, Baltimore

UM Ventures is a joint initiative of the University of Maryland, Baltimore and University of Maryland, College Park to commercialize technologies and expand industry collaboration.

Learn More